v-One hundred fifty-two intracranial gliomas of various types were reviewed in order to correlate the histopathological features with the proliferative potential of each tumor as reflected by the bromodeoxyuridine (BUdR) labeling index (LI). Patients undergoing surgical removal of gliomas were given a 30-minute intravenous infusion of BUdR (150 to 200 mg/sq m) to label S-phase tumor cells. The tumor specimens were stained immunohistochemically for BUdR and processed for routine histopathological diagnosis. The BUdR LI was calculated as the percentage of labeled cells among cells analyzed. Twenty-seven histological features in three categories (degenerative, vascular, and cellular changes) were considered. A significantly higher BUdR LI (p < 0.05) was found in tumors with necrosis than in those without this feature; tumors with both coagulative and liquefactive necrosis had the highest BUdR LI (p < 0.05). Increased vascularity was also associated with a higher BUdR LI (p < 0.05). Although tumors with abnormal mitotic figures had a significantly higher BUdR LI than those without, the number of mitoses did not correlate with a higher BUdR LI. These results suggest that the number of mitoses is not a good indicator of tumor growth rate. Necrosis and increased vascularity should be heavily weighted in predicting the proliferative potential of individual gliomas.
M
ALIGNANT gliomas account for 40% to 50% of the primary brain tumors diagnosed each year in the United States. 21 Even with aggressive therapy, the median survival time after diagnosis is only approximately 1 year. The degree and type of cellular abnormalities have long been known to influence the natural history of brain tumors, 38 and many grading systems have been devised based on this observation. 1~ Although widely used in diagnosis, none of these systems has gained general acceptance or has been unequivocally correlated with prognosis. 4 Because the cranium provides only a limited space in which a tumor may expand before it becomes fatal to the patient, the growth potential is a critical factor in the prognosis of patients with brain tumors. The need to measure the proliferative activity of tumors quantitatively in order to supplement the histopathological diagnosis has prompted the development of methods for estimating the cell cycle time, the duration of the S phase, and the growth fraction. [12] [13] [14] 22, 29, 40 Cell kinetics studies have been vigorously pursued for many years in an attempt to better understand tumor growth and to improve therapy. 13 The development of monoclonal antibodies against bromodeoxyuridine (BUdR), a halopyrimidine that is incorporated into nuclear deoxyribonucleic acid (DNA) during the S phase, 8'9 has greatly facilitated cell kinetics studies of brain tumors in situ. 16'17"23"24 The S-phase fraction, which can be determined by counting cells labeled with BUdR, provides an accurate estimate of the proliferative potential of the tumor. 12'22'39 The aim of this study was to identify histological features of gliomas that indicate their proliferative potential as reflected by the BUdR labeling index (LI). Degenerative and vascular changes as well as cellular abnormalities were evaluated to determine if any of these features can be used in diagnosing central nervous system (CNS) gliomas and in predicting their prognosis even when the BUdR LI is not available or cannot be obtained.
Clinical Material and Methods
Permission to administer BUdR was obtained from the Human Experimentation Committee at the Uni-versity of California, San Francisco (UCSF), and from the National Cancer Institute. Informed consent was obtained from each patient or a responsible relative. One hundred fifty-two patients with CNS gliomas were entered into the study. The male:female ratio was 1:5. The mean age (-+ standard deviation (SD)) was 35 +_ 2 years for males and 32 +_ 3 years for females. Each patient underwent surgical biopsy or excision of the tumor at UCSF. At the beginning of the operation, each patient received a 30-minute intravenous infusion of BUdR, 200 mg/sq m. The tumor specimens were divided into two portions. One portion was fixed in formalin, embedded in paraffin, cut into sections 6 to 8 um thick, and stained with hematoxylin and eosin for routine histological analysis. The other portion was fixed in chilled 70% ethanol, cut into sections 6 to 8 ~m thick, and stained immunohistochemically for BUdR. 23'24 The BUdR LI was calculated as the percentage of BUdR-positive cells among all cells in several high-power microscopic fields in which labeled cells were evenly distributed.
Tumors were diagnosed according to criteria used at UCSF. 6 Astrocytomas were classified as moderately or highly anaplastic based on the degree of cellularity, nuclear and cytoplasmic pleomorphism, vascular proliferation, and number of mitotic figures.
Histopathologicat Evaluation
A total of 678 pathological slides, or a mean of approximately four per patient, were reviewed by one of the authors (I.M.G.) without knowledge of the diagnosis, the location of the tumor, or the patient's medical history. Twenty-seven histological features in three categories were evaluated (Table 1) .
Degenerative Changes. The degenerative changes in brain tumors are mainly necrosis and cystic degeneration. 42 Two types of necrosis may be present. Coagulative necrosis is characterized by the persistence of cellular outlines after intracellular structures have been destroyed. Liquefactive necrosis is characterized by rapid enzymatic dissolution of the cells and their features, and is usually associated with coagulative necrosis. Necrosis was scored by type and by extent on a semiquantitative percentile scale. At times, foci of necrosis are surrounded by pseudopalisades (cells arranged side-by-side in rows with their processes facing inward). Cystic changes observable by light microscopy are often present in astrocytomas and ependymomas. These microcysts may contain hyaline proteinaceous fluid.
Vascular Changes. Increased vascularity compared
with normal brain is a fairly consistent feature of brain tumors. This feature was characterized by determining whether it was caused mainly by an increased number of medium-sized vessels or capillaries. Other vascular changes evaluated were the presence or absence of pseudoglomeruli (tufts of vascular endothelial proliferation), vessel-wall hyalinization (regressive cellular changes in the vessel wall in which the cytoplasm assumes a homoge-I. M. Germano, et al. Cellular Abnormalities. Cellular gigantism, abnormal mitotic figures, nuclear monstrosities, multinucleation, and nuclear pseudoinclusions (small amounts of hyaline material next to the nucleolus) were scored as present or absent. The number of mitoses was graded on a semiquantitative percentile scale. Increased cellularity was not included because this feature is already considered in the diagnosis of CNS gliomas at UCSF. 6 
Statistical Analysis
The data were analyzed by one-way analysis of variance (ANOVA), comparing each pathological feature to the average BUdR LI of each tumor; p less than or equal to 0.05 was considered significant. Bonferroni's method was used for the post hoc tests when necessary.
Data are expressed as the mean + SD in the text and tables and as the mean _+ standard error of the mean in the graphs.
Results
The percentage of tumor present on the pathological slides reviewed was above 75% of the tissue examined in 91% of the cases and less than 25% in 3% of the 
Degenerative Changes
Tumors with necrosis had significantly higher B U d R LI's than those without necrosis (p < 0.05). The BUdR LI's were significantly higher in tumors with coagulative and liquefactive necrosis (9.5%, p < 0.05) than in tumors without necrosis (3.2%) ( 
Vascular Changes
Tumors with increased vascularity had a higher B U d R LI than those without (6.8% vs. 4.2%, p < 0.05) (Fig. 4) . The B U d R LI was not significantly higher in tumors with any o f the other vascular abnormalities listed in Table 1 than in those without. or multinucleation (8.1% vs. 5.5%, p < 0.02) than in tumors without those features. No differences in BUdR LI were found comparing tumors without mitosis and those with rare or occasional mitoses. T u m o r s with " m a n y " mitoses, however, had a higher BUdR LI than those without mitoses (Fig. 5) .
Cellular Changes

Other Features
No statistically significant differences in the BUdR LI were seen in tumors with and without fibrosis, desmoplasia, p s a m m o m a bodies, tissue mineralization, Rosenthal fibers, or gemistocytes, or among gemistocytic tumors classified by quartile according to the percentage of gemistocytes present.
Discussion
The classification of supratentorial CNS gliomas is still controversial. 37 While the diagnosis of glioblastoma is always correlated with a poor prognosis, the malignancy of other types of anaplastic tumors varies widely even among tumors neuropathologically classified as belonging to the same group. Grading systems current-FIG. 5. No significant changes in the bromodeoxyuridine labeling index (BUdR LI) were found when comparing tumors with no mitoses, rare mitoses, and occasional mitoses. Tumors with many mitoses had significantly higher BUdR LI's than those without mitoses (p < 0.005). Circles represent individual cases.
ly based on cellular anaplasia 1~176 have often been criticized, and correlate poorly with clinical outc o m e . 25 '26'29 Even the definition of anaplasia may vary. According to Z i m m e r m a n , 41 anaplasia is the lack of cellular differentiation resulting in failure to achieve morphological maturity. In the American literature, anaplasia is mainly considered a process of cellular differentiation. 19 '28 In most grading systems, increased cellularity, pleomorphism of tumor cells, and an increase in the n u m b e r and abnormalities of mitoses are considered signs of malignancy. 19.28.31 The present study showed no correlation between mitosis and the BUdR LI except in tumors with m a n y mitoses and those with no mitoses. Thus, the n u m b e r of mitoses does not give any clue to the proliferative potential of individual gliomas. The identification of histological characteristics that correlate closely with the potential growth of each tumor should provide further prognostic information. It has been suggested that necrosis, one of the main regressive changes in CNS tumors, 34 correlates with a poor prognosis. 26 Massive necrosis is a common feature of glioblastomas, and necrotic foci may be present in astrocytomas, ependymomas, meduUoblastomas, and other tumors. 3~ Pseudopalisades are often associated with necrosis. When the necrosis is extensive, the pseudopalisades are usually long and undulating; when the necrotic focus is very small, they resemble pseudorosettes. The results presented here show that tumors with degenerative changes had a higher BUdR LI. Therefore, the presence, type (coagulative vs. coagulative and liquefactive), and pattern (pseudopalisades) of necrosis should be heavily weighted in predicting the growth potential of CNS gliomas.
Necrosis has been considered to develop as a result of vigorous cellular proliferation without an adequate blood supply. 35 Vascular abnormalities are common in brain tumors. 32 An increased number of capillaries and medium-sized vessels is often associated with proliferation of their vessel walls; mitotic figures may be identified in the endothelial cells. 34 At times, the vessels retain their thin-walled structure, become excessively convoluted, and form masses resembling renal glomerular tufts. 42 These changes are especially prominent in glioblastomas and may also be present in anaplastic gliomas. It has been suggested that increased vascularity is an early malignant change. 33 The present results show that increased vascularity is statistically associated with an increased S-phase fraction and therefore with a higher proliferative potential. Other vascular changes did not correlate with the BUdR LI.
The presence of gemistocytes has been considered a "malignant" feature. 7 Russell and Rubinstein 3~ suggested that some cerebral glioblastomas may have developed through anaplastic transformation from gemistocytic astrocytomas. However, Hoshino, et aL, TM reported that gemistocytes show little evidence of proliferative activity and suggested that other factors, such as focal hypoxia or starvation caused by malignant growth, might be responsible for the presence of swollen cells. This interpretation is supported by the observation that neither the presence nor the quantity of gemistocytes was associated with an increased S-phase fraction in the present study.
Although the BUdR LI provides an estimate of the proliferative potential, tumors with similar LI's may carry different prognoses. For example, glioblastomas and medulloblastomas both have a high proliferative potential as reflected by the BUdR LI) 5 This study reconfirms this observation, and demonstrates that necrosis is significantly more common in both of these tumors than in other gliomas. Yet, because medulloblastomas are much more sensitive to radiation therapy, patients with these tumors survive longer than those with glioblastomas.~-3'5"l 1,27,37
In conclusion, necrosis and increased vascularity are associated with higher proliferative potential in CNS ghomas and appear to be more reliable indicators of increased proliferative activity than are changes in cellularity alone. The results of this study therefore suggest that necrosis and increased vascularity should be heavily weighted in formulating routine diagnoses and in estimating the prognosis of patients with CNS gliomas.
